LXEO: רווח נקי למניה ב-12 החודשים האחרונים Lexeo Therapeutics

The DNA technology sector is currently experiencing a boom in genetic discoveries, and Lexeo Therapeutics (LXEO) is actively developing its pipeline of Alzheimer's treatments. The company's revenues are based on partnership payments and future licenses, while vector production and testing are fully outsourced to third-party contractors. Fundamental TTM earnings per share reflect a yield trend, with the current level sitting around -1.15.

This indicator is calculated as the ratio of total annual net income to the total number of shares outstanding, measuring the actual return on a single share of capital. The growth of the rolling 12-month EPS confirms the ability of Lexeo Therapeutics (LXEO) to monetize R&D developments in genetic medicine, converting scientific potential into financial stability and a hedge against inflationary costs.